Abeona Therapeutics Inc. (NASDAQ: ABEO) announced today updated clinical data from the Phase 1/2 trial for EB-101, the company’s gene-corrected ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Abeona Therapeutics (ABEO) Announces Clinical Update on MPS IIIA Gene Therapy TrialMay 18, 2018 9:27 AM Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT MeetingMay 17, 2018 9:20 AM Viking Global's 13F Shows New Stakes in Alibaba (BABA), BioMarin (BMRN) and Western Digital (WDC), Increase in Microsoft (MSFT), Wells Fargo (WFC) (More...)May 15, 2018 12:08 PM Abeona Therapeutics (ABEO) PT Lowered to $23 at SunTrust Robinson HumphreyMay 15, 2018 9:29 AM